Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients.
family history
germline
multigene panel testing
overall survival
pancreatic ductal adenocarcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Sep 2021
02 Sep 2021
Historique:
received:
16
07
2021
revised:
24
08
2021
accepted:
27
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
(1) Background: The proportion and spectrum of germline pathogenic variants (PV) associated with an increased risk for pancreatic ductal adenocarcinoma (PDAC) varies among populations. (2) Methods: We analyzed 72 Belgian and 226 Czech PDAC patients by multigene panel testing. The prevalence of pathogenic variants (PV) in relation to personal/family cancer history were evaluated. PDAC risks were calculated using both gnomAD-NFE and population-matched controls. (3) Results: In 35/298 (11.7%) patients a PV in an established PDAC-predisposition gene was found.
Identifiants
pubmed: 34503238
pii: cancers13174430
doi: 10.3390/cancers13174430
pmc: PMC8431631
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Kom op tegen Kanker
ID : STI.VLK.2017.0007.01
Organisme : Koning Boudewijnstichting
ID : 2017-J1140800- 207846
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : NU20-03-00285
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : RVO-VFN 64165
Organisme : Univerzita Karlova v Praze
ID : SVV 260516
Organisme : Univerzita Karlova v Praze
ID : PROGRES Q28/LF1
Références
Cancer Med. 2020 Jun;9(11):4004-4013
pubmed: 32255556
Cancer Manag Res. 2020 Jan 31;12:743-758
pubmed: 32099470
Pancreas. 2018 Sep;47(8):924-936
pubmed: 30113427
Cancer Lett. 2016 Jan 28;370(2):302-12
pubmed: 26546047
Genes Dev. 2014 Jan 1;28(1):1-7
pubmed: 24395243
Gut. 2020 Jan;69(1):7-17
pubmed: 31672839
Cancer. 2015 Dec 15;121(24):4382-8
pubmed: 26440929
Clin Cancer Res. 2020 Mar 15;26(6):1385-1394
pubmed: 31871297
Oncotarget. 2016 Nov 8;7(45):74227-74235
pubmed: 27732944
Genet Med. 2018 Jan;20(1):119-127
pubmed: 28726808
Gastroenterology. 2015 Mar;148(3):556-64
pubmed: 25479140
Int J Cancer. 2019 Oct 1;145(7):1782-1797
pubmed: 31050813
Lancet Oncol. 2020 Apr;21(4):508-518
pubmed: 32135080
Cancers (Basel). 2021 Jan 08;13(2):
pubmed: 33429865
Am J Hum Genet. 2004 Dec;75(6):1131-5
pubmed: 15492928
PLoS Genet. 2016 Aug 09;12(8):e1006248
pubmed: 27504877
PLoS One. 2018 Apr 12;13(4):e0195761
pubmed: 29649263
Cancer. 2018 Sep 1;124(17):3520-3527
pubmed: 30067863
Dtsch Arztebl Int. 2021 Mar 05;118(Forthcoming):
pubmed: 33531114
Int J Cancer. 2016 Aug 1;139(3):601-6
pubmed: 27038244
Mol Cancer Ther. 2019 Nov;18(11):1899-1908
pubmed: 31676541
Cancer Res Treat. 2017 Apr;49(2):430-436
pubmed: 27488870
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Clin Oncol. 2020 May 1;38(13):1442-1454
pubmed: 32073954
Br J Cancer. 2004 Mar 22;90(6):1244-51
pubmed: 15026808
Adv Surg. 2010;44:293-311
pubmed: 20919528
J Hum Genet. 2018 Apr;63(4):417-423
pubmed: 29403087
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Cancer. 2018 Apr 15;124(8):1691-1700
pubmed: 29360161
Genet Med. 2019 Jan;21(1):213-223
pubmed: 29961768
JAMA. 2018 Jun 19;319(23):2401-2409
pubmed: 29922827
Cells. 2020 Dec 12;9(12):
pubmed: 33322746
Front Oncol. 2015 Sep 29;5:208
pubmed: 26484312
Clin Cancer Res. 2020 Dec 15;26(24):6505-6512
pubmed: 33028596
Oncol Res Treat. 2018;41(10):611-618
pubmed: 30269130
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Gene. 2016 Aug 10;587(2):169-72
pubmed: 27150568
J Clin Oncol. 2017 Oct 20;35(30):3382-3390
pubmed: 28767289
Breast Cancer Res. 2005;7(5):R728-36
pubmed: 16168118